Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risedronic acid

Drug Profile

Risedronic acid

Alternative Names: Acrel; Actonel; Actonel Combi; Actonel plus Calcium; Actonel with Calcium; Atelvia; Benet; NE-58095; NE-58095NF; Optinate; Optinate Septimum; Ribastamin; Risedronate; Risedronate sodium; Sodium risedronate hydrate; WC3051

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Developer Ajinomoto; Allergan; Procter & Gamble; Sanofi; Takeda
  • Class Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteitis deformans
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Corticosteroid-induced osteoporosis; Male osteoporosis; Osteitis deformans; Osteoporosis; Postmenopausal osteoporosis
  • Discontinued Osteogenesis imperfecta

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 May 2017 Development of risedronic acid discontinued at phase II/III for Osteoporosis in Japan (PO,new tablet formulation) during 2016 (Takeda FY2016 results, May 2017)
  • 23 Mar 2015 Discontinued - Phase-III for Osteogenesis imperfecta (In children) in USA, Australia, Belgium, Chile, Czech Republic, Finland, Germany, Hungary, Italy, Poland, South Africa, Spain and the UK (PO, tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top